Don't be raped, robbed and injured by cel gene and receptors
Results: 9
Robert J. Hugin ("Bob") is the CEO of Celgene Corporation, a biopharmaceutical company with operations in more than 50 countries.[1]
Career
Mr. Hugin became the CEO of Celgene Corporation in June 2010 after already serving as their president and COO from May 2006. He was elected chairman in June 2011 by the Celgene Board of Directors. He first came to Celgene in June 1999 as a senior vice president and CFO and he was elected to their Board of Directors in December 2001.[1]From 1985 until April 1999, Mr. Hugin worked with J.P. Morgan & Co. Inc. and was a Managing Director.[2]
Other leadership roles
In April 2013, Mr. Hugin became the chairman of the Pharmaceutical Research and Manufacturers of America (PhRMA). He is also the Independent Director at The Medicines Co. and a Director at Choose New Jersey.[2] He is on many Board of Directors including: The Medicines Co., Atlantic Health System, Inc., Darden School Foundation, Princeton University, Family Promise and the University of Virginia Darden School of Business.[3] He was the Chairman of the HealthCare Institute of New Jersey. He also served as a United States Marine Corps infantry officer.[2]
Education
Mr. Hugin graduated from Princeton University in 1976 with an AB degree and graduated from the University of Virginia with an MBA in 1985.[4]
References
- ^ a b "Celgene’s Robert J. Hugin Becomes PhRMA Board Chairman". PHRMA. Retrieved 29 October 2014.
- ^ a b c "Robert J. Hugin". Business Week. Retrieved 29 October 2014.
- ^ "Robert J. Hugin". Market Watch. Retrieved 29 October 2014.
- ^ "Robert J. Hugin". Forbes. Retrieved 29 October 2014.
Headquarters
Business Development:busdev@receptos.com
Investor Relations:ir@receptos.com
General Information:info@receptos.com
Employment:humanresources@receptos.com
Investor Relations:ir@receptos.com
General Information:info@receptos.com
Employment:humanresources@receptos.com
NEW YORK — Cancer drug maker Celgene said it will buy Receptos for $7.32 billion in cash, gaining a drug Receptos is studying as a treatment for multiple sclerosis and ulcerative colitis.
Celgene agreed to pay $232 per share for Receptos, and the companies valued the deal at $7.2 billion excluding Receptos' cash on hand. That's a 12 percent premium from the Tuesday closing price of Receptos shares. The stock has surged more than fivefold over the last year as its drug ozanimod progressed in clinical testing.
Celgene Corp., based in Summit, New Jersey, reported about $2 billion in first-quarter sales of its drugs, which include the multiple myeloma treatments Revlimid and Pomalyst and breast and lung cancer drug Abraxane. Revlimid, its top seller, is also used to treat severe anemia and mantle cell lymphoma. The purchase of Receptos is part of a push to boost its sales of treatments for inflammatory and immune diseases. In 2014 Celgene launched its first drug in that category, the psoriasis and psoriatic arthritis treatment Otezla.
Receptos Inc. doesn't have any approved drugs on the market. The San Diego-based company expects results from late-stage trials of ozanimod in 2017 and 2018 and hopes to get the drug approved as a treatment for multiple sclerosis in 2018. In addition to ulcerative colitis, Receptos is also studying the drug as a treatment for inflammatory bowel disease. The companies said they think its annual sales could reach $6 billion.
In extended trading, Receptos shares added 10 percent, or $21.17, to $228.35. The stock closed at $37.75 a year ago.
Celgene shares rose nearly 6 percent, or $7.07, to $129.92 in late trading. Last month Celgene agreed to invest about $1 billion in drug developer June Therapeutics Inc., mostly by buying stock. The companies plan to develop cancer and autoimmune disease treatments.
No comments:
Post a Comment